Kinase News and Research

RSS

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

New breakthrough could lead to a cure for common childhood cancer

Scientists studying a common childhood cancer have made a major breakthrough which could lead to a cure for some youngsters who would not have survived the condition.

21 Jun 2021

Viral phosphoesterases (including in CoVs) can restrict antiviral innate immunity

An interesting new study describes the activities of a family of viral enzymes called two-histidine-phosphoesterases (2H-PEs), found in coronaviruses (CoVs) and rotaviruses, as well as a mammalian A-kinase anchoring protein enzyme, AKAP7, that shares the same function. Together called 2’,5’-PEs, these enzymes all break down 2’,5’-oligoadenylate compounds that activate the antiviral enzyme ribonuclease L (RNase L).

21 Jun 2021

Researchers propose new strategy for developing drugs based on inhibition of tyrosine kinases

A study performed by researchers at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) from the Spanish National Research Council (CSIC) in collaboration with Stony Brook University (USA) proposes a new strategy for the development of new drugs based on the inhibition of tyrosine kinase enzymes, molecules that activate and trigger many cellular processes. The results have been published in the Chemistry - A European Journal.

18 Jun 2021

Presence of certain stem cells linked to nongenetic resistance mechanisms of cancer cells

Cancer cells can develop resistance to therapy through both genetic and non-genetic mechanisms. But it is unclear how and why one of these routes to resistance prevails.

18 Jun 2021

Study may provide the basis to develop new therapies for urinary tract infections, kidney stones

The normal function of uromodulin, a protein that is made in the kidney and secreted into the urine, remains largely unknown. However, higher levels of uromodulin in the urine are related to lower rates of urinary tract infections and kidney stones, while higher levels of this protein in kidney cells are associated with higher rates of hypertension and chronic kidney disease.

17 Jun 2021

New computational topology strategy to identify existing medicines for treating COVID-19

Researchers from the ESI International Chair of the CEU Cardenal Herrera University (CEU UCH) and ESI Group have just published in scientific journal Pharmaceutics a new computational topology strategy to identify existing medicines that could be applied to treat COVID-19 without waiting for the research and clinical trial phases required to develop a new medicine.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Metformin prevents pulmonary or lung inflammation in animals infected with SARS-CoV-2

Metformin is a widely prescribed blood sugar-lowering drug. It is often used as an early therapy (in combination with diet and lifestyle changes) for type 2 diabetes, which afflicts more than 34 million Americans.

11 Jun 2021

Study: COVID-19 vaccines safe for IBD patients

Patients with inflammatory bowel diseases (IBD) do not appear to have increased risk of side effects from the Pfizer or Moderna COVID-19 vaccines, according to a recent Cedars-Sinai study published online and upcoming in print in the American Journal of Gastroenterology.

9 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

Genome-scale CRISPR screens pinpoint promising antiviral compounds against SARS-CoV-2

In a recent research paper currently available on the bioRxiv* preprint server, scientists in the US used genome-scale CRISPR knockout screens to identify factors that promote infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), revealing the potential for broad-spectrum activity across the coronavirus family.

7 Jun 2021

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.

7 Jun 2021

Two repurposed drugs inhibit SARS-CoV-2 entry factors in a synergistic manner

A preprint paper uploaded to the bioRxiv* server shows how combining drugs targeting different entry factors of the host cell may prevent infection by the virus.

3 Jun 2021

Cdkn1a transcript variant 2 is selectively elevated during natural aging across mouse tissues

Aging published "Cdkn1a transcript variant 2 is a marker of aging and cellular senescence" which reported that cellular senescence is a cell fate response characterized by a permanent cell cycle arrest driven primarily the by cell cycle inhibitor and tumor suppressor proteins p16Ink4a and p21Cip1/Waf1.

3 Jun 2021

Kinase News and Research

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

New breakthrough could lead to a cure for common childhood cancer

Viral phosphoesterases (including in CoVs) can restrict antiviral innate immunity

Researchers propose new strategy for developing drugs based on inhibition of tyrosine kinases

Presence of certain stem cells linked to nongenetic resistance mechanisms of cancer cells

Study may provide the basis to develop new therapies for urinary tract infections, kidney stones

New computational topology strategy to identify existing medicines for treating COVID-19

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Metformin prevents pulmonary or lung inflammation in animals infected with SARS-CoV-2

Study: COVID-19 vaccines safe for IBD patients

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Genome-scale CRISPR screens pinpoint promising antiviral compounds against SARS-CoV-2

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Two repurposed drugs inhibit SARS-CoV-2 entry factors in a synergistic manner

Cdkn1a transcript variant 2 is selectively elevated during natural aging across mouse tissues

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

Study identifies protein that could be the key to improving heart attack treatment outcomes

Researcher from Hollings Cancer Center wins Melanoma Research Alliance grant

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Light-controlled on/off switch helps control biological clock in cultured cells, explanted tissue

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News